ARVN · Company research
Arvinas, Inc (ARVN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
26records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth? | Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026. Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome | Krystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Arvinas, Inc. (ARVN) Stock Price, News, Quote & History - Yahoo! Finance Canada | Arvinas, Inc. (ARVN) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 14, 2026 | neutral | 0 | 0.6 |
| Reasons Why Investors Should Consider Betting on Arvinas Stock | Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Reasons Why Investors Should Consider Betting on Arvinas Stock | Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| TGTX Stock Rises 60% in 6 Months: Here's What You Should Know | TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| TGTX Stock Rises 60% in 6 Months: Here's What You Should Know | TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases | Mirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases | Mirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Arvinas (ARVN) Stock Price, News & Analysis - Stock Titan | Arvinas (ARVN) Stock Price, News & Analysis Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Brummer Multi-Strategy AB's Arvinas Inc(ARVN) Holding History - GuruFocus | Brummer Multi-Strategy AB's Arvinas Inc(ARVN) Holding History GuruFocus | View source ↗ | GuruFocus | Oct 12, 2026 | neutral | 0 | 0.6 |
| Arvinas, Inc. (NASDAQ:ARVN) Stock Has Average Price Target of $14.55 - MarketBeat | Arvinas, Inc. (NASDAQ:ARVN) Stock Has Average Price Target of $14.55 MarketBeat | View source ↗ | MarketBeat | Oct 8, 2026 | neutral | 0 | 0.6 |
| Arvinas, Inc. (ARVN) stock price, news, quote and history - Yahoo Finance Singapore | Arvinas, Inc. (ARVN) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 8, 2026 | neutral | 0 | 0.6 |
| Arvinas, Inc. (ARVN) stock price, news, quote and history - Yahoo Finance UK | Arvinas, Inc. (ARVN) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 7, 2026 | neutral | 0 | 0.6 |
| Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease | Arvinas presented Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, showing dose-dependent improvements in oculomotor function and correlations between LRRK2 reduction and improvements in biomarkers related to endolysosomal function, neuroinflammation, and synaptic integrity in Parkinson's disease patients. The findings support continued clinical evaluation of ARV-102 for neurodegenerative diseases associated with LRRK2 dysregulation. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease | Arvinas presented Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, showing dose-dependent improvements in oculomotor function and correlations between LRRK2 reduction and improvements in biomarkers related to endolysosomal function, neuroinflammation, and synaptic integrity in Parkinson's disease patients. The findings support continued clinical evaluation of ARV-102 for neurodegenerative diseases associated with LRRK2 dysregulation. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| A 28-day study found less severe eye-movement impairment with Arvinas' Parkinson's drug candidate. - Stock Titan | A 28-day study found less severe eye-movement impairment with Arvinas' Parkinson's drug candidate. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits | ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule Stocktwits | View source ↗ | Stocktwits | Oct 5, 2026 | neutral | 0 | 0.6 |
| Parkinson’s drug trial data will be presented in a late-breaking oral session - Stock Titan | Parkinson’s drug trial data will be presented in a late-breaking oral session Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Arvinas (ARVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España | Arvinas (ARVN) Stock Analysis Report | Ratings, Financials & Performance Benzinga España | View source ↗ | Benzinga España | Sep 27, 2026 | neutral | 0 | 0.6 |
| ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits | ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff Stocktwits | View source ↗ | Stocktwits | Sep 26, 2026 | neutral | 0 | 0.6 |
| ARVN News | ARVINAS INC (NASDAQ:ARVN) - ChartMill | ARVN News | ARVINAS INC (NASDAQ:ARVN) ChartMill | View source ↗ | ChartMill | Sep 26, 2026 | neutral | 0 | 0.6 |
| Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish (NASDAQ:ARVN) - Seeking Alpha | Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish (NASDAQ:ARVN) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 28, 2026 | neutral | 0 | 0.6 |
| Arvinas (ARVN) Stock Jumps As Profit Windfall Sparks Durability Debate - Simply Wall Street | Arvinas (ARVN) Stock Jumps As Profit Windfall Sparks Durability Debate Simply Wall Street | View source ↗ | Simply Wall Street | Aug 5, 2026 | neutral | 0 | 0.6 |
| Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance | Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 4, 2026 | neutral | 0 | 0.6 |
| ARVN Forecast — Price Target — Prediction for 2027 - TradingView | ARVN Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.